BiotechTube
Essential Pharmaceuticals

Essential Pharmaceuticals

Princeton, United States· Est.
essentialpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Essential Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the transplant medicine market with its cornerstone product, Custodiol® HTK. Acquired by Accord Healthcare in 2017, the company leverages a focused sales and marketing team to serve a well-defined niche. Its business is centered on a single, established product, positioning it as a specialized player in the cardiovascular and organ preservation space, with a historical focus that also includes metabolic and rare diseases.

CardiovascularMetabolicRare Disease

Technology Platform

Commercial platform focused on identifying, acquiring, and marketing established specialty pharmaceutical products for niche therapeutic areas, with deep expertise in the transplant community.

Funding History

1
Total raised:$10M
Series A$10M

Opportunities

The stable and essential organ transplant market provides a consistent revenue base, with potential to expand usage of Custodiol HTK.
Backing by Accord Healthcare enables potential portfolio diversification through acquisition of additional niche products in cardiovascular, metabolic, or rare disease areas.
Existing deep relationships with transplant centers offer a platform for launching new, related products.

Risk Factors

Extreme product concentration risk with reliance on a single commercial product, Custodiol HTK.
Faces competition in the organ preservation market and general pricing pressures in healthcare.
Strategic direction and resource allocation are dependent on parent company Accord Healthcare's priorities.

Competitive Landscape

Custodiol HTK competes in the organ preservation solutions market against other static cold storage solutions like University of Wisconsin (UW) solution and Perfadex. The competitive landscape is well-established with a few key players. Essential's strategy is based on specialized marketing and deep customer relationships rather than technological disruption in this mature segment.

More companies in Small Molecule Drugs →More companies in United States →